The effect of smoking cessation pharmacotherapies on pancreatic beta cell function

Toxicology and Applied Pharmacology

Volumn 265, Issue 1, 2012, Pages 122-127

  Woynillowicz, Amanda K ^a   Raha, Sandeep ^a   Nicholson, Catherine J ^a   Holloway, Alison C ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Bupropion; Diabetes; INS 1E cells; Mitochondrial dysfunction; Nicotine; Varenicline

Indexed keywords

AMFEBUTAMONE; GLUCOSE; VARENICLINE;

ANIMAL CELL; ARTICLE; CELL LINE; CELL STIMULATION; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; GLYCEMIC CONTROL; IN VIVO STUDY; INSULIN RELEASE; NICOTINE REPLACEMENT THERAPY; NONHUMAN; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; RAT; RESPIRATORY CHAIN; SMOKING CESSATION PROGRAM;

ANIMALS; BENZAZEPINES; BUPROPION; DOPAMINE UPTAKE INHIBITORS; ELECTRON TRANSPORT; GENE EXPRESSION; GLUCOSE; INSULIN; INSULIN-SECRETING CELLS; MITOCHONDRIA; NICOTINE; NICOTINIC AGONISTS; OXIDATIVE STRESS; PANCREATIC FUNCTION TESTS; QUINOXALINES; RATS; SIGNAL TRANSDUCTION; SMOKING; SMOKING CESSATION;

RATTUS;

EID: 84868304353     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2012.08.020     Document Type: Article

References (41)

1. Assali A.R., Beigel Y., Schreibman R., Shafer Z., Fainaru M. Weight gain and insulin resistance during nicotine replacement therapy. Clin. Cardiol. 1999, 25:357-360.
2. Bellmann K., Wenz A., Radons J., Burkart V., Kleemann R., Kolb H. Heat shock induces resistance in rat pancreatic islet cells against nitric oxide, oxygen radicals and streptozotocin toxicity in vitro. J. Clin. Invest. 1995, 95:2840-2845.
3. Benowitz N.L. Nicotine addiction. N. Engl. J. Med. 2010, 362:2295-2303.
4. Bruin J.E., Gerstein H.C., Morrison K.M., Holloway A.C. Increased pancreatic beta-cell apoptosis following fetal and neonatal exposure to nicotine is mediated via the mitochondria. Toxicol. Sci. 2008, 103:362-370.
5. Bruin J.E., Petre M.A., Lehman M.A., Raha S., Gerstein H.C., Morrison K.M., Holloway A.C. Maternal nicotine exposure increases oxidative stress in the offspring. Free Radic. Biol. Med. 2008, 44:919-1925.
6. Bruin J.E., Petrik J.J., Hyslop J.R., Raha S., Tarnopolsky M.A., Gerstein H.C., Holloway A.C. Rosiglitizone improves pancreatic mitochondrial function in an animal model of dysglycemia: the role of the insulin-like growth factor axis. Endocrine 2010, 37:303-311.
7. Bullen C., McRobbie H., Thornley S., Glover M., Lin R., Laugesen M. Effect of an electronic nicotine delivery device (e cigarette) on desire to smoke and withdrawal, user preference and nicotine delivery: randomized cross-over trial. Tob. Control 2010, 19:98-103.
8. Crowley-Weber C.L., Dvorakova K., Crowley C., Bernstein H., Bernstein C., Garewal H., Payne C.M. Nicotine increases oxidative stress, activates NF-kappaB and GRP78, induces apoptosis and sensitizes cells to genotoxic/xenobiotic stresses by a multiple stress inducer, deoxycholate: relevance to colon carcinogenesis. Chem. Biol. Interact. 2003, 145:53-66.
9. DeVeaugh-Geiss A.M., Chen L.H., Kotler M.L., Ramsay L.R., Durcan M.J. Pharmacokinetic comparison of two nicotine transdermal systems, a 21-mg/24-hour patch and a 25-mg/16-hour patch: a randomized, open-label, single dose, two-way crossover study in adult smokers. Clin. Ther. 2010, 32:1140-1148.
10. Drews G., Krippeit-Drews P., Dufer M. Oxidative stress and beta-cell dysfunction. Eur. J. Physiol. 2010, 460:703-718.
11. El-Dakhakhny M., Abdel El-Latif H.A., Ammon H.P. Different effects of the antidepressant drugs imipramine, maprotiline and bupropion on insulin secretion from mouse pancreatic islets. Arzneimittelforschung 1996, 46:667-669.
12. Eliasson B., Taskinen M.R., Smith U. Long-term use of nicotine gum is associated with hyperinsulinemia and insulin resistance. Circulation 1996, 94:878-881.
13. Epifano L., Di V.A., Fanelli C., Porcellati F., Perriello G., De F.P., Motolese M., Brunetti P., Bolli G.B. Effect of cigarette smoking and of a transdermal nicotine delivery system on glucoregulation in type 2 diabetes mellitus. Eur. J. Clin. Pharmacol. 1992, 43:257-263.
14. Ezzati M., Lopez A.D. Estimates of global mortality attributable to smoking in 2000. Lancet 2003, 362:847-852.
15. Faessel H.M., Obach R.S., Rollema H., Ravva P., Williams K.E., Burstein A.H. A review of the clinical pharmacokinetics and pharmacodynamics of varenicline for smoking cessation. Clin. Pharmacokinet. 2010, 49:799-816.
16. Figueiredo P.A., Ferreira R.M., Appell H.J., Duarte J.A. Age-induced morphological, biochemical, and functional alterations in isolated mitochondria from murine skeletal muscle. J. Gerontol. A Biol. Sci. Med. Sci. 2008, 63:350-359.
17. Gallo C., Renzi P., Loizzo S., Loizzo A., Piacente S., Festa M., Caputo M., Tecce M.F., Capasso A. Potential therapeutic effects of vitamin E and C on placental oxidative stress induced by nicotine: an in vitro evidence. Open Biochem. J. 2010, 4:77-82.
18. Halima B.A., Sarra K., Kais R., Salwa E., Najoua G. Indicators of oxidative stress in weanling and pubertal rats following exposure to nicotine via milk. Hum. Exp. Toxicol. 2010, 29:489-496.
19. Hsyu P.H., Singh A., Giargiari T.D., Dunn J.A., Ascher J.A., Johnston J.A. Pharmacokinetics of bupropion and its metabolites in cigarette smokers versus nonsmokers. J. Clin. Pharmacol. 1997, 37:737-743.
20. Hughes J.R. Effects of abstinence from tobacco: valid symptoms and time course. Nicotine Tob. Res. 2007, 9:315-327.
21. Inoue K., Takeshima F., Kadota K., Yoda A., Tatsuta Y., Nagaura Y., Yoshioka S., Nakamichi S., Nakao K., Ozono Y. Early effects of smoking cessation and weight gain on plasma adiponectin levels and insulin resistance. Intern. Med. 2011, 50:707-712.
22. Jang E.H., Park C.S., Kang J.H. Bupropion, an atypical antidepressant, induces endoplasmic reticulum stress and caspase-dependent cytotoxicity in SH-SY5Y cells. Toxicology 2011, 285:1-7.
23. Kaneto H., Kawamori D., Matsuoka T.A., Kajimoto Y., Yamasaki Y. Oxidative stress and pancreatic beta-cell dysfunction. Am. J. Ther. 2005, 12:529-533.
24. Kovacic P. Mechanism of varenicline (clinical ramifications): electron transfer and oxidative stress. Med. Hypotheses 2007, 68:1184-1185.
25. Kraiczi H., Hansson A., Perfekt R. Single-dose pharmacokinetics of nicotine when given with a novel mouth spray for nicotine replacement therapy. Nicotine Tob. Res. 2011, 13:1178-1182.
26. Lenzen S., Drinkgern J., Tiedge M. Low antioxidant enzyme gene expression in pancreatic islets compared with various other mouse tissues. Free Radic. Biol. Med. 1996, 20:463-466.
27. Maechler P., de Andrade P.B. Mitochondrial damages and the regulation of insulin secretion. Biochem. Soc. Trans. 2006, 34:824-827.
28. McNeil J.J., Piccenna L., Ioannides-Demos L.L. Smoking cessation-recent advances. Cardiovasc. Drugs Ther. 2010, 24:359-367.
29. Ohtani M., Oka T., Badyuk M., Xiao Y., Kellar K.J., Daly J.W. Mouse beta-TC6 insulinoma cells: high expression of functional alpha3beta4 nicotinic receptors mediating membrane potential, intracellular calcium, and insulin release. Mol. Pharmacol. 2006, 69:899-907.
30. Parise G., Phillips S.M., Kaczor J.J., Tarnopolsky M.A. Antioxidant enzyme activity is up-regulated after unilateral resistance exercise training in older adults. Free Radic. Biol. Med. 2005, 39:289-295.
31. Patti M.E., Corvera S. The role of mitochondria in the pathogenesis of type 2 diabetes. Endocr. Rev. 2010, 31:364-395.
32. Potts L.A., Garwood C.L. Varenicline: the newest agent for smoking cessation. Am. J. Health Syst. Pharm. 2007, 64:1381-1384.
33. Rustemeier K., Stabbert R., Haussmann H.J., Roemer E., Carmines E.L. Evaluation of the potential effects of ingredients added to cigarettes. Part 2: chemical composition of mainstream smoke. Food Chem. Toxicol. 2002, 40:93-104.
34. Slemmer J.E., Martin B.R., Damai M.I. Bupropion is a nicotinic antagonist. J. Pharmacol. Exp. Ther. 2000, 295:321-327.
35. US Public Health Services A clinical practice guideline for treating tobacco use and dependence: A US Public Health Service report. The Tobacco Use and Dependence Clinical Practice Guideline Panel, Staff, and Consortium Representatives. JAMA 2000, 283:3244-3254.
36. Wallace D.C. A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine. Annu. Rev. Genet. 2005, 39:359-407.
37. Wang J., Kim J.M., Donovan D.M., Becker K.G., Li M.D. Significant modulation of mitochondrial electron transport system by nicotine in various rat brain regions. Mitochondrion 2009, 9:186-195.
38. Wetscher G.J., Bagchi M., Bagchi D., Perdikis G., Hinder P.R., Glaser K., Hinder R.A. Free radical production in nicotine treated pancreatic tissue. Free Radic. Biol. Med. 1995, 18:877-882.
39. Willi C., Bodenmann P., Ghali W.A., Faris P.D., Cornuz J. Active smoking and the risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2007, 298:2654-2664.
40. Yoshikawa H., Hellstrom-Lindahl E., Grill V. Evidence for functional nicotinic receptors on pancreatic beta cells. Metabolism 2005, 54:247-254.
41. Zhao Z., Reece E.A. Nicotine-induced embryonic malformations mediated by apoptosis from increasing intracellular calcium and oxidative stress. Birth Defects Res. B Dev. Reprod. Toxicol. 2005, 74:383-391.